

## **Redaction & Confidentiality Log – Request for Emergency Exemption**

Per OAR 409-070-0070 and other applicable law, this document identifies those documents that are exempt from public disclosure, and explains the grounds for such exemption. Under OAR 409-070-0070(3), “[c]onfidential materials filed by an applicant in connection with a [HCMO] transaction that is subject to review by . . . the [Oregon Health] Authority . . . must be maintained as confidential materials in accordance with . . . ORS 415.501(13)(c).” Under ORS 415.501(13)(c), the Oregon Health Authority “shall maintain the confidentiality of all confidential information and documents that are not publicly available that are obtained in relation to a [HCMO] material change transaction.” Such information is “exempt from disclosure under ORS 192.311 to 192.478 [the Public Records Act].” The documents and information identified below are confidential and contain information that is not publicly available. Therefore, the applicant respectfully ask that the Oregon Health Authority maintain the confidentiality of such documents and not release any such documents under the Oregon Public Records Act.

This document in no way limits either party’s right to assert additional or alternative grounds for exemption from the Oregon Public Records Act. The applicant respectfully requests highly confidential treatment under all applicable statutes, rules, and regulations. Without prejudice to the rights of Asante and its subsidiaries (“Asante”), or Southern Oregon Surgery Center, LLC (“SCSO”), if the Oregon Health Authority or Department of Justice should at any time contemplate disclosing any redacted, or otherwise confidential or privileged, materials to the public or to any third party for any reason and for any use—including but not limited to quoting from, attaching, or otherwise referring to such documents in a court or administrative proceeding whether filed under seal or publicly—we request an opportunity of no fewer than three days’ advance notice to allow sufficient time to object and, if necessary, seek protections against disclosure from a court of competent jurisdiction.

Reference	Party Information	Information Redacted	Basis for Redaction
HCMO-2 Form Pages 3-4	SCSO	Solvency data	SCSO requests confidential treatment of this information. As a nonpublic entity, this information has not been made publicly available in any other forum. Under ORS § 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. This information is competitively sensitive, and disclosure could be used by others for business advantage. Therefore, this information is protected as a “trade secret” under ORS § 192.345(2) and further protection under ORS § 192.355(9)(a) and ORS § 646.461 et seq. As such, SCSO is requesting further confidential treatment of this information unless SCSO provides its written consent to publication.
HCMO-2 Form Page 3	SCSO	Future strategic plans for SCSO	CSO requests confidential treatment of this information. As a nonpublic entity, this information has not been made publicly available in any other forum. Under ORS § 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. This information is competitively sensitive, and disclosure could be used by others for business advantage. Therefore, this information is protected as a “trade secret” under ORS § 192.345(2) and further protection under ORS § 192.355(9)(a) and ORS § 646.461 et seq. As such, SCSO is requesting further confidential treatment of this information unless SCSO provides its written consent to publication.
HCMO2: Asante/SCSO, Appendix A, Bates No. 8-13	SCSO	All information in the Financial Health Presentation	SCSO requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. Under ORS § 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. This information is competitively sensitive, and disclosure could be used by others for business advantage. Therefore, this information is protected as a “trade secret” under ORS § 192.345(2) and further protection under ORS § 192.355(9)(a) and ORS § 646.461 et seq. As such, SCSO is requesting further confidential treatment of this information unless SCSO provides its written consent to publication.
HCMO2: Asante/SCSO, Appendix B, Bates No. 14-137	SCSO	All information contained in the Cash runway analysis and Financial Statements	SCSO requests confidential treatment of this document. As a nonpublic entity, this information has not been made publicly available in any other forum. Under ORS § 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. This information is competitively sensitive, and disclosure could be used by others for business advantage. Therefore, this information is protected as a “trade secret” under ORS § 192.345(2) and further protection under ORS § 192.355(9)(a) and ORS § 646.461 et seq. As such, SCSO is requesting further confidential treatment of this information unless SCSO provides its written consent to publication.
HCMO2: Asante/SCSO, Appendix C, Bates No. 138-143	Asante and SCSO	All information contained in the Term Sheet	The Parties request confidential treatment of this information. This information has not been made publicly available in any other forum. Under ORS § 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing confidential information and documents that are not publicly available that are obtained in relation to a material change transaction. Further, this information reflects a compilation of internal strategic information, including but not limited to considerations regarding potential future geographies and service lines, and Asante’s method of

Reference	Party Information	Information Redacted	Basis for Redaction
			<p>valuation. The information has been maintained as confidential among members of SCSO and counsel. This information is competitively sensitive, and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model. Therefore, this information is protected as a "trade secret" under ORS § 192.345(2) and further protection under ORS § 192.355(9)(a) and ORS § 646.461 et seq. As such, the parties are requesting further confidential treatment of this information unless the parties provide written consent to publication.</p>